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ABSTRACT
This report is the third in a series of summaries produced in connection with the operations research project,
Enhancing Access to Family Planning Services through the Introduction of Emergency Contraception. The project
was launched in September 1997 to explore a broad range of issues surrounding the introduction and delivery of
emergency contraception services in a developing country context.
The study described in this report compares the introduction of two different emergency contraception pills: the
combined oral contraceptive PC-4, introduced into Zambia in 1997, and the progestin-only contraceptive,
Postinor-2, which was introduced by this study in the following year. The impetus for the study evolved out of
two concerns expressed at a 1998 national workshop on emergency contraception. The first was that Schering
AG, the manufacturer of PC-4, might block moves to broaden the range of facilities providing the product,
despite indications that doing so would make emergency contraception more accessible to thousands of Zambian
women. Elsewhere, the manufacturer had prevented the registration of PC-4 on similar grounds, and it was
feared that they might do so again in Zambia. The second impetus for comparing the two products was the
growing body of evidence to suggest that progestin-only pills might actually be a better product than the
combined oral regimen, both in terms of reducing side-effects and limiting the number of unwanted pregnancies.
Service providers, therefore, were eager to see for themselves what impact, if any, a progestin-only alternative
might have on improving overall quality of care.
Because Zambia’s experience with emergency contraception had been, prior to this study, based solely on the
delivery of PC-4, the objective of this research was to explore whether the lessons learned in connection with
that product would still be applicable should circumstances necessitate the registration of an alternative
emergency contraception pill. The goal of this exercise, therefore, was to provide an empirical basis for
generalizing the lessons learned to date through the introduction of PC-4. To accomplish this, the study
compared 1) differences in the service delivery requirements associated with the provision of the two methods;
2) variations in the range, frequency and/or severity of side effects attributable to the two methods; and 3) any
discrepancies in client attitudes and behavior that might be method-related.
The research design entailed replicating activities previously undertaken to introduce PC-4, but among a
different group of public-sector health care facilities in Lusaka. The study entailed three major sets of activities:
provider training; the delivery of emergency contraception services; and the collection of service statistics and
other data on potential and actual users of emergency contraception services. Results were then compared across
the two groups of health care facilities.
Study results revealed that despite the earlier introduction of PC-4, clients at the two groups of facilities
evidenced few differences in knowledge or attitudes. Both groups, for example, were equally likely to claim they
knew ways of preventing a pregnancy after unprotected intercourse and equally unlikely to identify a correct
response. Clients at the Postinor-2 clinics were no more likely than those at the PC-4 clinics either to recognize
the name “emergency contraception”, or to be aware that oral contraceptives could be used for emergency
purposes. Given this lack of familiarity, the study recommended that a more systematic dissemination of
information on the method be undertaken.
Acceptance rates of the two products followed similar trajectories. Both began gradually, peaked at around 4-6
months, and then leveled off. Although the volume of PC-4 distributed exceeded that of Postinor-2, the
disparity was attributable to differences in the sizes of the two catchment areas, to provider concerns over the
long-term availability of Postinor-2, and even to provider-preferences for PC-4 itself. Not only did many
providers believe Postinor-2 to be “more experimental” than PC-4 but, in contrast to their clients, most
providers were already familiar with PC-4 by the time the study had begun. Given the potential impact of such
provider preferences, the study recommended that until Zambia’s regulatory authorities selected an emergency
contraception product for approval, IEC efforts should remain brand-neutral and focus more on the possibilities
of preventing unwanted pregnancies, than on the technical or commercial attributes of any particular emergency
contraception pill.
The second issue to be addressed in this study concerned the impact of reduced levels of side effects associated
with use of Postinor-2 on client behavior and services. Of particular concern was the fear that a “more
tolerable” emergency contraceptive method might remove incentives for women to shift to routine family
planning methods. Overall, the results of this study suggest only a weak relationship between side effects and the

adoption of routine family planning. Most emergency contraception users eventually adopted a routine family
planning method, regardless of whether they used PC-4 or Postinor-2. With respect to the transition to
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more effective contraceptive methods, the similarities across groups once again outweighed differences. Among
all women who returned for their follow-up visit and chose a family planning method, the adoption of highly
effective, essentially hormonal methods, reached levels of 90 percent and above. Finally, regarding the attitudes
of emergency contraception users towards the methods themselves, client histories showed only minor
differences. Of the 59 Postinor-2 users who returned to follow up, only one said she would not recommend the
method to a friend; the reason given being method failure. A slightly higher percentage of former PC-4 users
said they would not recommend the method; but in both cases, method approval exceeded 95 percent.
The study concludes by arguing that, at the service delivery level, the similarities between PC-4 and Postinor-2
greatly overshadow their differences. Family planning users display few preferences or aversions towards either
product. They adopt both at comparable rates and, after having used them, manifest few if any differences in
their appreciation of either product; in their decision to adopt a family planning method, or even in their choice
of method itself. From a provider-perspective, similarities also overshadow differences.
But the study also highlights important differences between the two products; some of which could very well
have implications for the delivery of services. One such difference relates to supply and logistics. One
advantage of a combined oral regimen is that it can always be substituted by regular oral contraceptives. In the
event of product stockouts or in an environment of cost cutting, PC-4 can be replaced – and done so more
cheaply – by existing supplies. Postinor-2, by contrast, has no true equivalent within the range of methods
typically available at health care facilities. An entire cycle of minipills might offer the same level of hormones as
a single tablet of Postinor-2, but it is not certain the progestins contained in them would be metabolized in the
same way or even whether women would be willing to ingest an entire cycle of pills at one time. Furthermore,
substitution would not provide any cost savings since the unit price of Postinor-2 and a cycle of minipills is
essentially the same.
On the other hand, however, the study also points out some important shortfalls of the combined oral regimen –
the most notable being its comparatively high levels of side effects and its lesser efficacy at preventing
pregnancies. As this study makes clear, no one factor alone will ever determine whether PC-4 or Postinor-2
represents the ideal product for the Zambian context. Cost, efficacy, level of side effects, flexibility in
distribution, and the potential for donor procurement must all – to some degree -- enter into the equation. What
the present study does show, however, is that in arriving at their decision, Zambia’s health planners and
regulatory authorities can build with confidence on the body of service delivery information accumulated since
the introduction of PC-4. Though substantive differences between the two products do indeed exist, these
differences do not call for new training programs, different client support mechanisms, or even distinctive
strategies for the dissemination of information.

NOTE DE SYNTHESE
Ce rapport est le troisième d’une série de comptes rendus produits dans le cadre d’un projet de recherche
opérationnelle intitulé «Améliorer l’Accès aux Services de Planification Familiale à travers l’Introduction à la
Contraception d’Urgence». Ce projet a été lancé en septembre 1997 afin d’étudier plusieurs points portant sur
l’introduction et la prestation des services de contraception d’urgence dans le contexte d’un pays en voie de
développement.
L’étude décrite dans ce rapport fait la comparaison de l’introduction de deux différentes pilules contraceptives
d’urgence (PCU): le contraceptif combiné, PC-4, introduit en Zambie en 1997, et le contraceptif progestatif,
Postinor-2, introduit par la présente étude l’année suivante. La décision d’entreprendre cette étude a répondu à
deux préoccupations exprimées au cours d’un atelier national sur la contraception d’urgence, tenu en 1998. La
première préoccupation était que Schering AG, fabriquant de PC-4, pourrait faire obstruction aux démarches
visant l’élargissement de la gamme des points d’offre du produit, même si en agissant ainsi, cela rendrait la
contraception d’urgence plus accessible aux milliers de femmes. Le fabriquant avait déjà empêché la
reconnaissance officielle de PC-4 dans d’autres pays et l’on craignait qu’il fasse de même en Zambie. La
seconde motivation pour la comparaison des deux produits était cependant l’évidence suggérant que le régime
progestatif pourrait être en réalité meilleur que le régime combiné, en termes de diminution aussi bien des effets
secondaires que du nombre de grossesses indésirables. Les prestataires de services étaient donc curieux de
constater par eux-mêmes quel impact ce régime alternatif pourrait avoir sur l’amélioration globale de la qualité
des soins.
L’expérience de la Zambie en matière de contraception d’urgence ayant été ainsi basée jusque là sur
l’approvisionnement en PC-4 uniquement, l’objectif premier de cette étude était de chercher à savoir si les
leçons apprises de cette expérience seraient toujours applicables au cas où les circonstances nécessiteraient la
reconnaissance d’une autre pilule contraceptive d’urgence. Le but de cette opération, par conséquent, était de
fournir des bases empiriques visant à généraliser les leçons apprises avec l’introduction préalable de PC-4. Pour
ce faire, l’étude a comparé les différences entre les conditions requises pour la prestation des deux méthodes; la
gamme, la fréquence et/ou la gravité des effets secondaires liés à l’emploi des deux méthodes; et entre les
conséquences de telles différences sur les attitudes ou comportement du client.
Le plan de recherche a consisté en la reproduction des activités déjà entreprises pour le lancement de PC-4, mais
cette fois-ci, pour un différent groupe de centres de santé du secteur public à Lusaka. L’étude comprenait trois
séries d’activités, à savoir: la formation des prestataires; la prestation des services de contraception d’urgence; et
le rassemblement de statistique sur les services et d’autres données concernant les utilisatrices potentielles et
réelles des services de contraception d’urgence. Par la suite, les résultats ont été comparés en tenant compte de
ces deux groupes de centres de santé.
Malgré le fait que PC-4 avait été introduit il y a un an, les résultats de recherche sur les clientes des deux
groupes ont révélé peu de différences quant à leurs connaissances et attitudes. Les deux groupes, par exemple,
prétendaient tout aussi bien savoir comment éviter la grossesse suite aux rapports sexuels sans protection et en
même temps incapables d’identifier une réponse correcte. Les clientes aux “ cliniques Postinor-2 ” comme celles
aux “ cliniques PC-4 ” avaient les mêmes chances, soit de reconnaître le nom “contraception d’urgence”, soit
d’être au courant que les pilules contraceptifs pourraient être pris en cas d’urgence. Vu ce manque de
connaissance, l’étude recommande une dissémination plus systématique des informations relatives à la méthode.
Les taux d’approbation des deux produits ont suivi des trajectoires semblables. Après avoir graduellement
commencé ; l’approbation des deux produits a atteint son maximum au bout de 4-6 mois environ, puis elle s’est
stabilisée. Bien qu’on ait distribué plus de PC-4 que de Postinor-2, la disparité était fonction des différences
dans la taille des deux zones de couverture, des soucis des prestataires sur la disponibilité à long terme de
Postinor-2, et des préférences des prestataires pour PC-4 elle-même. Beaucoup de prestataires ont perçu
Postinor-2 comme étant « plus expérimentale » que PC-4 et, contrairement à leurs clientes, la plupart des
prestataires connaissaient bien déjà la contraception d’urgence et même la marque PC-4. Etant donné l’influence
possible des préférences de ces prestataires, l’étude a recommandé, qu’en attendant que les autorités concernées
en Zambie choisissent de reconnaître un seul produit de contraception d’ urgence, les efforts de l’IEC devraient
rester neutres envers la marque et porter plus sur les possibilités d’éviter les grossesses non désirées que sur les
attributs commerciaux d’une quelconque PCU.

La deuxième question abordée dans cette étude était l’impact des niveaux réduits des effets secondaires de
Postinor-2 sur le comportement des clientes et les services rendus à ces dernières. La plus grande préoccupation
était qu’une méthode de contraception d’urgence “plus supportable” ne motive plus de femmes à adopter les
méthodes usuelles de planification familiale. D’une façon générale, les résultats de cette étude indiquent un
rapport faible entre les effets secondaires et l’adoption d’une méthode usuelle. Sans distinction de choix entre
PC-4 et Postinor-2, la plupart des utilisatrices de contraception d’urgence ont éventuellement adopté une
méthode de planification familiale usuelle. Quant à la transition aux méthodes anticonceptionnelles plus
efficaces, les similarités parmi les groupes ont encore une fois dépassé les différences. Parmi toutes les femmes
qui sont revenues pour leur visite de contrôle et qui ont choisi une méthode de planification familiale, l’adoption
des méthodes très efficaces et essentiellement hormonales a atteint au moins 90 pour-cent. En dernier lieu,
relativement aux attitudes des utilisatrices de la contraception d’urgence envers les méthodes elles-mêmes, les
antécédents médicaux ont révélé peu de différences. Sur les 59 utilisatrices de Postinor-2 qui sont venues pour la
visite de contrôle, il n’y a qu’une seule qui a dit qu’elle ne recommanderait pas cette méthode à une amie; la
raison donnée étant l’échec de la méthode. Un pourcentage un peu plus élevé des anciennes utilisatrices de PC-4
ont affirmé qu’elles ne recommanderaient pas la méthode; mais dans les deux cas, l’approbation de la méthode a
dépassé 95 pour-cent.
L’étude conclut en affirmant qu’au niveau de la prestation des services, les similitudes entre PC-4 et Postinor-2
obscurcissent les différences. Les utilisatrices de planification familiale montrent peu de préférences ou
d’aversions pour les deux produits. Elles en adoptent à des taux comparables, et après les avoir employés,
manifestent peu de différences dans leur appréciation des deux produits; en ce qui concerne leur décision
d’adopter une méthode de planification familiale usuelle; ou même leur choix de méthode. Du point de vue du
prestataire aussi, les similarités dépassent les différences.
Mais l’étude met également en lumière d’énormes différences importantes entre les deux produits, et certaines de
ces différences pourraient avoir des conséquences sur la prestation des services. Une différence se rapporte par
exemple aux provisions et à la logistique. L’un des atouts d’un régime de PCU combiné est qu’il peut être
toujours remplacé par des contraceptifs combinés usuels. En cas d’épuisement de stocks ou d’un plan de
réduction des coûts, PC-4 peut toujours être remplacé d’une manière moins coûteuse par les provisions
disponibles. Postinor-2, par contre, n’a pas d’équivalent réel dans la gamme de méthodes disponibles dans les
centres médicaux. Tout un cycle de mini pilules pourrait offrir le même niveau d’hormones contenues dans un
seul cachet de Postinor-2, mais il n’est pas certain que les hormones qu’il contient ne soient transformées par le
métabolisme de la même manière; ou que les femmes acceptent d’ingérer tout un cycle de pilules d’un seul coup.
De plus, la substitution n’était pas rentable car le prix unitaire de Postinor-2 et celui d’un cycle de mini pilules
est presque le même.
Cependant, parallèlement, la littérature disponible met également en relief certains inconvénients du régime
combiné, notamment ses taux d’effets secondaires comparativement élevés et son efficacité moindre dans la
prévention de la grossesse. Comme le démontre clairement la présente étude, aucun facteur pris isolement ne
peut déterminer lequel des produits, PC-4 ou Postinor-2, représenterait le produit idéal pour la Zambie. Coût,
efficacité, taux d’effets secondaires, flexibilité de distribution et probabilité d’obtention de bailleurs -- tous ces
facteurs doivent, dans une certaine mesure, entrer dans l’équation. Ce que cette étude démontre en réalité, est
que quelque soit le produit choisi, les agents de planification de la santé et les autorités réglementaires peuvent
bénéficier de l’ensemble des informations rassemblées depuis l’introduction de PC-4 en matière de prestations
de services. Il est vrai qu’il existe des réelles différences entre les deux produits, mais celles-ci ne nécessitent pas
de nouveaux programmes de formation, des mécanismes différents de soutien pour les clientes ou même des
stratégies distinctives pour la dissémination des informations.
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1. INTRODUCTION
This report is the third in a series of summaries produced in connection with the
operations research project, Enhancing Access to Family Planning Services through the
Introduction of Emergency Contraception. Launched in September 1997, the project explored
the broad range of issues surrounding the introduction and delivery of emergency
contraception services in a developing country context.1 The first phase of the project, which
concluded in March 1998, was an exploratory exercise, designed to identify strategies for
overcoming difficulties associated with the introduction of emergency contraception. The
second phase, of which this study is a part, uses operations research to test the problemsolving strategies identified in Phase One.
The study described in this report compared the introduction of two different emergency
contraception pills: the combined oral contraceptive PC-4, first introduced into Zambia by
this project in 1997, and the progestin-only contraceptive, Postinor-2, developed under the
sponsorship of the International Consortium on Emergency Contraception. Implemented at
four public sector clinics in Lusaka, Zambia, the study sought to identify whether there were
any differences in the service delivery requirements associated with the provision of the two
methods; in the range, frequency and/or severity of side effects associated with the use of the
two methods; and in the consequences of such differences on client attitudes or behavior.
Ultimately, the goal of this exercise was to provide an empirical basis for generalizing the
lessons learned under Phase One of this project should circumstances require the registration
and introduction of an emergency contraception product, other than PC-4.
This report follows the structure of the previous two research summaries (Ahmed et al 1998;
Skibiak et al 1999). The first section recounts the events and circumstances that led to the
development of this study; it details the interventions tested; and it describes the rationale
underlying the selection of these particular interventions. The next section follows with a
summary of the study’s research methodology and principal data collection activities. The
fourth and fifth chapters detail the research findings and outline their implications for future
programmatic activities. Finally, the discussion concludes with a review of areas for
subsequent action.
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Emergency contraception refers to methods women can use to prevent pregnancy following unprotected
intercourse. There are several types of emergency contraception. The most widely used involves oral
contraceptive pills taken within 72 hours of intercourse, followed by an additional number 12 hours later. The
number of pills taken will vary, depending on their hormonal composition and dosage. One regimen, commonly
referred to as “Yuzpe”, involves the provision of two high-dose combined oral contraceptive tablets (each
containing levonorgestrel, 250cg plus ethinyl estradiol, 50cg) followed by a further two tablets 12 hours later.
The product PC-4 is an example of the Yuzpe regimen packaged specifically for emergency contraception use.
Another regimen involves the initial provision of one tablet containing 750cg levonorgestrel, followed by
another tablet 12 hours later. This progestin-only formulation has been packaged and marketed under the brand
name Postinor-2.
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2. BACKGROUND
A

critical stage in the development of any strategy for contraceptive introduction is the
identification of a product whose formulation, dosage, or even brand name can be deemed
appropriate for the local environment.

In September 1997, the Population Council’s Africa OR/TA II project launched an operations
research study entitled Enhancing Access to Family Planning Services through the Introduction
of Emergency Contraception. Implemented by Lusaka’s University Teaching Hospital, the
study introduced into Zambia for the first time a single dedicated product containing four high
dose oral contraceptive tablets, each containing levonorgestrel, 250cg plus ethinyl estradiol,
50cg. Manufactured under the brand name PC-4, this product is one of the world’s leading
emergency contraception methods. It is registered in over eight countries, including the
United Kingdom, Switzerland, Germany, and South Africa.
By any standards, the introduction of PC-4 in Zambia has been an unmitigated success.
Through the involvement of four major providers of reproductive health services (University
Teaching Hospital, the Ministry of Health/Central Board of Health, the Planned Parenthood
Association of Zambia, and the University of Zambia) emergency contraception is now
available at more than 21 health care facilities across Lusaka and the rural Copperbelt. Since
September 1997, over 1,500 packets have been dispensed through the project.
Though client history records indicate that the efficacy, side effects and client perceptions of
PC-4 are very much in line with the existing literature, a review (Ahmed et al. 1998) of the
study’s Phase One findings recommended exploring the acceptability of another widely-used
emergency contraceptive product, Postinor-2, manufactured by Gedeon Richter, Ltd.
Currently in use by the International Consortium on Emergency Contraception, Postinor-2 is
a progestin-only formulation, consisting of only two tablets, each containing levonorgestrel,
750cg.
De-medicalizing emergency contraception: The recommendation to introduce Postinor-2
reflected two broad concerns to emerge from Phase One of the study. The first was the
opportunity it offered to expand the number and range of outlets through which emergency
contraception services could be made available. A key finding of the Phase One review was
that traditional clinic-based facilities were failing to reach many of those most in need of
emergency contraception. This included both in- and out-of-school youth as well as the
majority of women who regularly engage in unprotected intercourse, yet do not feel at risk of
becoming pregnant (Ahmed et al., 1998: 13). To reach these populations, the review called
for greater de-medicalization of emergency contraception services and, more specifically, for
a diversification of the kinds of outlets through which it might be provided. These outlets
might include, for example, community-based distributors, pharmacies or even peer
counselors.
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Though the call for demedicalization was supported by a broad cross-section of Zambia’s
reproductive health community2, one potential obstacle facing such a move was the longstanding resistance of PC-4’s manufacturer, Schering AG, to over-the-counter sales of its
products, or to local registration efforts that failed to guarantee strict medical supervision of
product distribution. (Ellis 1998, Consortium for Emergency Contraception 1996: 9).
Obviously, this stance presented the project – and indeed the health care community as a
whole – with a potential predicament. What if, for example, research were to suggest that
non-clinical distribution of emergency contraception pills held the greatest potential for
reaching under-served populations? Zambia might very well find itself in the position of
either: 1) being refused Schering’s support to register PC-4; or 2) being provided support for
registration only under the condition that it accept distribution arrangements that would
effectively place the product beyond reach of those whose unmet need for emergency
contraception was greatest.
Figure 1
POSTINOR-2 and PC-4

The decision to introduce an alternative contraceptive product, therefore, was seen as the
most effective means to expand the contraceptive options available for review by Zambia’s
chief regulatory agency, the Drug and Poisons Board. By demonstrating the acceptability –
or even comparability – of an alternative emergency contraception product, it was hoped that
the future role of emergency contraception in Zambia would be better able to reflect the
reproductive health needs of Zambia’s women.
2

On 10 March 1998, a national workshop was held to disseminate the findings of Phase One of the present
operations research study. Attended by more than 80 participants representing the service delivery, academic, and
NGO/international donor communities, it was from this workshop that the recommendation emerged to expand the
range of potential emergency contraception providers. For a more detailed account of the workshop proceedings,
see Ahmed et al (1998).
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The choice of Postinor-2 as the alternative option was a logical one insofar as the product
itself was the result of a collaborative agreement between its manufacturer, Gedeon Richter,
and the International Consortium on Emergency Contraception. At the latter’s request,
Gedeon Richter repackaged its popular 750cg levonorgestrel tablets, previously marketed
under the brand name “Postinor”, into two-tablet packages suitable for one-time emergency
contraception use. Up until that point, Postinor had been registered in 29 countries, including
Kenya, Zimbabwe, Nigeria, all of Eastern and Central Europe and the former Soviet Union
(Camp 1998: 225). In 1997, the new “Postinor-2”, became the sole emergency contraception
product for use in all research and service delivery trials carried out under the auspices of the
International Consortium.
Reducing the side-effects of emergency contraception: In addition to broadening the range
of contraceptive options, there was another reason for exploring the acceptability of Postinor2. It was the increasing body of evidence suggesting that it might actually offer certain
advantages over the combined Yuzpe regimen, of which PC-4 is an example.
Though the range and severity of side effects associated with PC-4 in this study were in line
with those reported elsewhere in the literature, overall, providers still felt their incidence was
high: over 80 percent of the women who received emergency contraception through this study
experienced at least some side effect. Levels of nausea were particularly high, even
exceeding those reported by Ho and Kwan in their 1993 study comparing levonorgestrel with
the Yuzpe regimen (see Figure 2).
Figure 2
Frequency of Side Effects Associated with Use
of Yuzpe Regimen
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In reviewing the findings of Phase One, a number of reasons were suggested as to why the
level of side effects under this study could have varied from those reported in Ho and Kwan.
One explanation was simply a discrepancy over definitions: women who might otherwise
have reported mild vomiting (which, incidentally, occurred less frequently than in Ho and
Kwan’s study), for example, could have described their symptoms as nausea. Another was
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differences in the quality of counseling, particularly with respect to the importance of taking
emergency contraception with food as a means to reduce nausea (Hatcher et al 1994: 443). A
third explanation, however, was the product itself. In Ho and Kwan’s (1993) study, for
example, nausea associated with the use of a progestin-only emergency contraception pill
(such as Postinor-2) was reduced by as much as 65 percent, vomiting by 88 percent, dizziness
by 20 percent and breast tenderness by 24 percent.
Because previous clinical trials had already compared and documented the technical efficacy
of different emergency contraception formulations, there was little point in doing so again if
the only outcome were to be similar sets of technical data. Instead, what the present study
sought to do was to explore the impact of these technical differences on client attitudes and
assess the implications of such differences for the service delivery system. Ultimately, it was
hoped that the results of this research would make it possible to determine whether the
lessons learned to date in connection with PC-4 could, in fact, be generalized in the event it
became necessary to explore the registration and introduction of an alternative emergency
contraception product. In that sense, therefore, the objectives of this project were really quite
modest. Ultimately, they sought to show that the consequences of delivering Postinor-2, if
not better, would at least be comparable to those associated with the delivery of PC-4.
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3. OPERATIONS RESEARCH STUDY
Launched in April 1998, the ultimate objective of this study was to accumulate enough firsthand experience with the delivery of Postinor-2 to be able to answer the following questions:
•
•

Are there any significant differences in the service delivery requirements associated
with the provision of Postinor-2 as opposed to PC-4?
Are there any significant differences in the range, frequency and/or severity of side
effects associated with the use of Postinor-2 as opposed to PC-4? Should such
differences exist, do they influence client attitudes or behavior?

The design of the study entailed a replication of activities previously undertaken to introduce
PC-4, but among a different group of public sector clinics. Three major sets of activities were
carried out: provider training; the delivery of emergency contraception services; and the
collection of service statistics and other data on potential and actual users of emergency
contraception services. Results were then compared across the two groups of health care
facilities.

PROVIDER TRAINING
From 26-29 June 1998, eight health care providers from four Lusaka-based health facilities
(Chelstone, Kabwata, Kamwala and George clinics) were trained in emergency contraception.
Because of a 1997 directive by the Zambia Central Board of Health banning all off-site
training workshops, training was carried out on-site at each participating health care center.
Training lasted one day and utilized the same materials adopted during Phase One of the
operations research study. The materials were drawn from the packet published by the
Consortium for Emergency Contraception. Each participant was also provided with a
complete set of materials for use during the training and to keep as a permanent reference
source. Finally, a locally produced pre- and post-test instrument was used to evaluate
technical knowledge.

DELIVERY OF EMERGENCY CONTRACEPTION SERVICES
A fundamental premise of WHO's Strategy for Contraceptive Introduction and Technology
Transfer is that any new method must be provided within the context of a broad contraceptive
choice so that the focus of the introductory effort is not on one single method, but on the
strengthened delivery of all methods (Simmons et al 1997: 79-94). From the very outset, the
study has adhered closely to this philosophy by training and equipping only those providers and
health facilities capable of offering their clients a full range of reversible and permanent
methods. With these criteria in mind, the four public sector clinics selected to participate in
this study3 all had MCH/FP staff trained to provide general family planning services and were
3

All of these health centers offer their clients a full range of reversible methods. Permanent methods and
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comparable in terms of client characteristics, staffing, and infrastructure to the four clinics
involved in Phase One (see Figure 3).
In June 1998, all four centers began providing Postinor-2 to clients who requested treatment
for unprotected intercourse, method failure, or rape. After receiving emergency contraception
services, the women were asked if they would be willing to participate in the present study.
They were given a brief description of the aims of the project; they were told that all information
collected from them would be stored securely; and they were assured that the written results of
research findings would not include any details that could identify them.
Figure 3
Geographic Distribution of Health Center Catchment Areas
Receiving PC-4 and Postinor-2

All supplies of Postinor-2 used in this project were made possible through the support of the
International Consortium on Emergency Contraception, WHO’s Special Programme of
Research, Development and Research Training in Human Reproduction, and Gedeon Richter,
Ltd.

DATA COLLECTION
Three major data collection activities took place during this study. They included:

longer-term methods such as Norplant® and the IUD are also available, either on-site or through referral.
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SURVEY OF MCH/FP CLIENTS: From 28 May to 8 September, 1998, a survey of knowledge,
attitudes and practices (KAP) towards emergency contraception was administered to 1,600
women attending MCH/FP services at the four public sector health centers involved in this
phase of the study. The survey instrument and data collection/analysis procedures were
identical to the those used six months earlier in a KAP survey of 1,600 MCH/FP clients at the
clinics involved in Phase One of the study. The objective of the survey was threefold. First, it
was carried out in order to establish the comparability of the client population involved in
Phase One of the study with those attending the four clinics involved in this intervention.

The second reason for implementing the survey was to ensure that the interventions
undertaken during this phase mirrored those carried out previously. In Phase One, for
example, it was found the survey had had a notable effect on communicating information
about emergency contraception to both MCH/FP clients and the community at large. There
were even indications that the questionnaire provided a “trigger” or “on-the-spot” source of
information for women who, though unaware of its existence beforehand, were in a position
to have actually benefited from it. To ensure that recipients of Postinor-2 received the same
information as that provided to users of PC-4, the survey was repeated using the same
instrument and data collection/analysis procedures.
Finally, for data collection purposes, the survey proved to be a useful research tool for
obtaining insight into women’s awareness, beliefs, and sources of information about strategies
used to prevent unwanted pregnancy. During the survey, clients were given a description of
emergency contraception and then asked to indicate their impressions of it, whether they might
ever use it, what they found most intriguing about it, and the range of persons they felt they
could turn to for information on it.
CLIENT HISTORY FORMS: Client history forms were opened for all participants who received
Postinor-2 though this study. Identical to those used by PC-4 recipients during Phase One,
the forms consisted of three parts. The first examined the circumstances surrounding the act
of unprotected intercourse that prompted the client to request emergency contraception. The
second part, which is completed during the initial follow-up visit, sought information on such
factors as side effects, effectiveness, and general attitudes towards the emergency
contraceptive pill used. The third section recorded whether the client chose to adopt a routine
family planning method, what that method was, and the circumstances surrounding that
decision.

All client history forms were kept at the service delivery point for a period of two months or
until the client returned for follow-up. Any client not returning after two months was
considered lost to follow-up. Forms were then turned over to the project for continuous data
entry.
PROVIDER INTERVIEWS: At the conclusion of this study, interviews were carried out among
the providers at each of the participating health care facilities. The interviews sought to gauge
provider knowledge and attitudes towards emergency contraception and discern service delivery
patterns that might be attributed to provider attitudes and biases. During the interviews,
providers were asked to reflect upon overall use patterns of emergency contraception at their
clinic; the circumstances under which they would and would not recommend emergency
contraception; and what they saw its shortfalls to be.
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4. IS THE ENVIRONMENT
RIGHT FOR ANOTHER METHOD?
In August 1997, the emergency contraception pill, PC-4, was introduced into 21 health care
facilities across Lusaka and the rural Copperbelt. Among these facilities were Lusaka’s
University Teaching Hospital, fifteen health centers within the Central Board of Health, four
clinics operated by the Planned Parenthood Association of Zambia, and the main campus clinic
of the University of Zambia. To date over 1,500 women have received PC-4 through this study.
Many thousands more have been informed about it as the only means available to prevent
unwanted pregnancies after unprotected intercourse.
Although no effort was made to publicize the availability of emergency contraception beyond
the original 21 clinics, distribution of PC-4 has clearly increased over the last 18 months. The
method has even established itself within the marketplace, with reports of pharmacies and drug
venders charging up to 10,000 Kwacha per packet (approximately US$4.25) – nearly 20 times
the price of the leading socially marketed brand of oral contraceptives. Even at the health center
level, distribution of PC-4 has expanded beyond the sites originally affiliated with this project.
Accounts of PC-4 usage have been reported as far away as Livingstone and Kabwe.
In addition to greater utilization of PC-4, knowledge about the product has particularly
expanded among health care providers. Prior to the introduction of the method, 89 providers
were trained in emergency contraception at three separate one-day workshops. All of these
individuals returned to their respective health centers where many, through routine
procurement channels, obtained PC-4 and began providing it to their clients.
It was, therefore, against this backdrop of broad product dissemination, extensive provider
training and increasing brand recognition that the decision was made to introduce Postinor-2
into four public sector health care facilities distributed across Lusaka. One of the most
immediate issues to be addressed by the study, therefore, was to determine whether such preexposure to PC-4 would influence the acceptability or adoption of a new emergency
contraception product. Obviously, the answer to this question would have a direct bearing on
the supposed “comparability” of the two products, since existing attitudes, positive or negative,
could easily have undermined the introduction and/or acceptability of Postinor-2 at the outset.
The first issue to be addressed by the study, therefore, focussed specifically on factors
associated more with the public image or knowledge of emergency contraception, than with the
behavioral consequences of actually having used an emergency contraception product itself.
Were the clients of the four health centers, for example, truly comparable to those at the
centers where PC-4 had been originally introduced? Did the interventions, training and
dissemination activities that took place during the first year of this project really influence
knowledge or attitudes about emergency contraception, or about PC-4 specifically? And
thirdly, did acceptance rates of the two products follow a similar trajectory? Was one more
readily accepted than the other, or did they both follow comparable distribution levels?

9

Research findings:

To assess the comparability of factors likely to influence product acceptability, a survey of
knowledge, attitudes and practices (KAP) towards emergency contraception was administered
to 1,600 women attending MCH/FP services at the four “Postinor-2 clinics” involved in this
phase of the study. As noted previously, the survey instrument was identical to the one
applied 6-12 months earlier at five of the 21 facilities involved in Phase One of the study
where PC-4 was administered.
Overall, the survey results revealed striking similarities in the client populations of the two
groups of clinics. Though age distribution varied slightly from clinic to clinic, between
groups, the pattern was virtually identical (see Figure 4)

Figure 4
Age Distribution of MCH/FP Clients
at PC-4 and Postinor-2 Clinics
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Educational levels of the two groups were also virtually identical, with roughly 40 percent of
all clients having completed primary school, 40 percent having completed secondary school
and the remainder divided evenly between those who had attended, but not necessarily
completed university or primary school.
A third potential determinant of emergency contraception use, contraceptive prevalence, also
proved to be strikingly similar, with 75 percent of clients (N=1,176) at the PC-4 clinics
claiming to be current users of a family planning method, versus 69 percent (N=1,107) at the
Postinor-2 clinics. Even the distribution of the methods was virtually alike, with pills and
injectables making up 84 and 87 percent, respectively, of the method mix; while condoms
accounted for no more than 5 percent of all users in either group (see Figure 5).
Ultimately, however, the principal objective of these comparisons was to gauge whether preexposure to PC-4 – or even to the concept of emergency contraception, itself – stood to
influence client acceptability of a new method such as Postinor-2.
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Figure 5
Method Mix of Family Planning Users at MCH/FP Facilities
of PC-4 and Postinor-2 Clinics
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In several respects, the results of the KAP survey proved quite surprising. For one thing, they
show that despite the “backdrop of broad product dissemination”, there were no notable
differences in knowledge and attitudes towards emergency contraception between the Postinor2 clinics and the PC-4 clinics. Both groups, for example, were equally likely to claim they
knew ways of preventing pregnancy after unprotected intercourse (38.9 and 36.8 percent,
respectively). Furthermore, as shown in Figure 6, their delineation of different solutions was
virtually identical. In both cases, traditional remedies such as the ingestion of nonprescription drugs (especially iron tablets or chloroquine); the drinking of various herbal
infusions, or the insertion into the vagina of foreign objects were cited most often. This was
followed by some (usually incorrect) regimen of pill use, and then by the identification of
emergency contraception by name. Indeed, clients at the Postinor-2 clinics were no more
likely than those at the PC-4 clinics, either to recognize the name “emergency contraception”,
or to be aware that oral contraceptives could be used for emergency purposes. Furthermore,
in both surveys, the primary source of information about emergency contraception (at least for
those who knew about it) was the clinic itself, followed by friends.
What these findings suggest, therefore, is that despite the higher mobility and greater social
complexity of urban populations, the catchment areas of the different health centers may be
much more circumscribed than is typically assumed. At one level, this finding speaks directly
to the need for more broad-based IEC strategies on emergency contraception. At another,
however, it suggests that – at least at this stage – knowledge of emergency contraception is
still limited enough to ensure that a larger scale introduction of Postinor-2 would not likely be
encumbered by preconceptions concerning either PC-4, or emergency contraception in
general.
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Figure 6
Solutions Identified by MCH/FP Clients
for Preventing Pregnancy after Unprotected intercourse
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Perhaps it is for that reason that when one compares the actual acceptance rates of the two
products over the first eight months of their availability, both followed a similar trajectory
(see Figure 7). Acceptance of both began gradually, peaked at around 4-6 months, and then
leveled off as clients better understood the role and effectiveness of emergency contraception
in general. As was discovered during Phase One of the project, providers claimed that the
initial surge in demand for emergency contraception was partially attributable to erroneous
beliefs among some clients that it might also work an abortifacient (Ahmed et al 1998: 5).
The decline in utilization, they argued, was the gradual result of continued IEC efforts and
simply the personal experience of those who had used it unsuccessfully.
Although the distribution of PC-4 clearly exceeded that of Postinor-2 in absolute terms, the
difference appears to have had little to do with prior client exposure to PC-4. For one thing,
the sizes of the two catchment areas were quite different. The catchment population of the
facilities offering PC-4, for example, was over 20 percent larger than that of the centers
offering Postinor-2. In addition, PC-4 was made available through the national IPPF affiliate,
PPAZ, at three of its health care facilities. The level of the each center’s family planning
activities also differed. Kanyama Clinic (in the PC-4 group), for example, averaged over 30
new family planning acceptors per month, compared to the monthly averages at the George
and Chelstone clinics which barely exceeded 2.
Another factor that may have contributed to a lower distribution of Postinor-2, were provider
concerns over the long-term availability of the product. In the case of PC-4, at least 50,000
units of the product had been purchased two years earlier by the British Overseas
Development Administration. Although 2,000 packets of Postinor-2 had been ordered for the
present study, initial delays made it necessary to begin project activities with a minimal
supply of only 50. The fact that each health center was issued an initial allotment of only 10
packets (with 10 held in reserve by the project) clearly gave rise to doubts among providers
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over the adequacy of existing stocks. Consequently, until the full stock of commodities
arrived in August, 1998, some providers admitted having first “used up” their existing stocks
of PC-4, before distributing Postinor-2. Only in August (month 3 of the study) were all
remaining PC-4 packages removed from the four participating clinics.

Figure 7
Quantities of PC-4 and Postinor-2 Distributed per Month
At Participating Health Care Centers
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Finally, a third factor that may have contributed to the comparatively lower distribution of
Postinor-2, was the perception among some providers that Postinor-2 was somehow more
“experimental” than the better known and more widely used PC-4. In interviews, providers
often claimed that PC-4 had already become so synonymous with emergency contraception,
that clients were requesting it by name. While there is no reason to doubt that such requests
did occur from time to time, it is unlikely such requests could have ever been considered
routine, particularly since the results of the KAP survey questionnaire gave no indication that
knowledge of emergency contraception, let alone PC-4, was that widespread.
In short, if brand preferences had indeed exerted any influence over the distribution curve, in
all likelihood it was the preferences of providers. Many providers had, after all, already been
trained to provide PC-4. And although every effort was made to dismiss any suggestion that
Postinor-2 was experimental, no efforts were made to present it as a better product either.

Conclusions:

Despite apparent increases in the provision of emergency contraception pills, it is clear that
public awareness of the method has remained limited to the catchment areas in which it
currently being distributed4. To many in this study, such findings may be come as a
4

KAP studies carried out among MCH/FP clients at both the PC-4 and Postinor-2 show a consistent increase
over time in the number of respondents who correctly identify emergency contraception as a means of avoiding
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disappointment – particularly given the intensity of project interventions; the number of
health care providers trained in the method; and the fact that PC-4 is now in stock at more
than 21 health care facilities across Lusaka and the rural Copperbelt.
But the irony of this discovery, is that it captures perhaps better than any other observation,
both the challenges and opportunities that lay ahead in the effort to enhance access to
emergency contraception services. On the one hand, it clearly points to the need for a more
systematic attempt at disseminating information on emergency contraception – one that does
not rest exclusively on direct provider-client interaction or less-formal channels of
communication. Word of mouth can indeed be an extremely effective medium for
communicating information, but for such information to spread beyond the catchment areas
themselves, or to reach populations that do not routinely attend the health facilities (ie. youth,
unmarried women), a wider, more systematic IEC effort will be required.5
On the other hand, however, these results also show that even if general information about
emergency contraception has not spread widely, provider preferences can exert a powerful
force on method selection. Providers were, for example, the ones most familiar with PC-4
and that familiarity clearly manifested itself in the frequency with which they distributed both
it and Postinor-2.
What this suggests, therefore, is that until Zambian regulatory authorities select an emergency
contraception product for regulatory approval, IEC efforts should probably remain brandneutral and focus more on the possibilities of preventing unwanted pregnancies in general,
than on the technical or commercial attributes of any particular emergency contraception pill.
Enough examples exist of both approaches to provide guidance to health care planners and
providers in Zambia.6

pregnancy after unprotected sexual intercourse (see Ahmed et al 1998: 12).
5
The Phase One results, for example, showed that within the catchment areas of each health center, knowledge
of emergency contraception spread quite rapidly.
6
In the United States and United Kingdom, IEC campaigns on emergency contraception have typically adopted
a more indirect approach towards information dissemination, focussing primarily on the service options available
to women in the event of unprotected intercourse. Often, these messages provide emergency phone numbers or
the locations where services can be obtained. Obviously, one advantage of such a neutral approach, is that leaves
open (though primarily to the provider) the specific type or brand of emergency contraception to be used.
In the developing world, by contrast, IEC has focussed very much on brand recognition. In Kenya, for example,
the International Consortium on Emergency Contraception has produced posters and pocket calendars
emblazoned with photos of the product used there, Postinor-2. In South Africa, a somewhat similar approach
has been adopted in for Schering’s “E-GEN-C”, the local brand name for PC-4. One advantage of focussing on
the brand-name is that it shifts responsibility for product identification to the client – an appropriate strategy in
settings where providers might not be familiar with emergency contraception.
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5. DO FEWER SIDE EFFECTS MAKE A
DIFFERENCE?
All

hormonally-based emergency contraception regimens entail some side effects. Those
associated with the PC-4, for example, include the same range of effects commonly experienced
with short-term use of combined oral contraceptives, though with higher frequency.
In Zambia, experience with the delivery of PC-4 suggested that both the range and frequency of
side effects were very much in line with those reported in the literature. Indeed, except in the
case of nausea, the frequencies of vomiting, breast tenderness and dizziness were actually
lower than the figures cited in Ho and Kwan (1993). But however “in line” they may have
been technically speaking, for many providers involved in this study, they were still too high:
over 80 percent of all women who received PC-4, for example, experiencing at least some
effect.
For at least a decade, research has shown that the frequency of side effects associated with
progestin-only regimens of emergency contraception is significantly less than those associated
with the use of combined oral contraceptives. Ho and Kwan, for example, argued that
progestin-only emergency contraception pills (such as Postinor-2) could reduce the nausea
associated with the Yuzpe regimen by as much as 65 percent, vomiting by 88 percent,
dizziness by 20 percent and breast tenderness by 24 percent. Earlier studies by Glasier (1992)
and Webb (1992) showed even greater reductions in the frequency of nausea and vomiting.
Although the present study also expected to observe these lower frequencies within Zambia,
its primary goal was to understand what these reductions might mean for the service delivery
system as well as for client attitudes and behavior. Would a reduction in the frequency of
side effects, for example, impact on frequencies of return to follow-up; or on the subsequent
adoption of a regular family planning method; or even on client/provider preferences between
brands? In other words, did the use of Postinor-2 lead to a reduction in side effects
associated with the use of emergency contraception, and if so what difference did that
reduction make?7
Research Findings:

In this study, the primary source of data on the follow-up and management of secondary
effects were client records opened on all emergency contraception users. As noted
previously, the client history consisted of three parts. The first examined the circumstances
surrounding the act of unprotected intercourse that led to the request for emergency
contraception. The second sought information on such factors as side effects, effectiveness,
and general attitudes towards the emergency contraception product used; while the third

7

In addition to reducing levels of nausea and vomiting, there is solid evidence to suggest that a levonorgestrelonly regimen of emergency contraception may actually be more effective at preventing pregnancy (Task Force
1998: 428-433; Von Hertzen 1998: 222-232; Von Hertzen et al 1998: 1939). For further information on this
issue, see page 21, below).
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recorded whether the client chose to adopt a routine family planning method, what that
method was, and the circumstances surrounding that decision.
Based on the results of 268 client history forms completed by the end of February 1999, the
use of Postinor-2 did indeed reduce dramatically the level of side-effects associated with PC4 during Phase One of the study8. As shown below in Figure 8, it accomplished this by
halving levels of nausea, virtually eliminating vomiting altogether, and as Ho and Kwan
predicted, by reducing breast tenderness and dizziness.

Figure 8
Comparison of Side Effects
Associated With Use of Postinor-2 and PC-4
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But did these declines in the frequency of side effects lead to any commensurate differences
in either client behavior or in provider attitudes towards the new method?
Routine use of emergency contraception: While there is still much debate over the causal
nature of linkages between enhanced access and repeat use of emergency contraception
(Glasier et al 1998; Skibiak et al 1999), one of the strongest arguments against habitual use of
emergency contraception is that the side effects alone would probably discourage most
women from using it routinely. Indeed, avoidance of side effects was singled out during
Phase One of this study as one of the more likely explanations for the dramatic shift among
former emergency contraception users towards more effective, hormonal methods (Ahmed et
al. 1998: 27-29).

8

Completed client histories refer to those client cases in which health care staff have completed all three
sections of the client history form. Completed client histories would exclude both emergency contraception
users lost to follow-up (failed to return within two months of initial visit) and those who had still not returned.
The 209 completed PC-4 histories were collected over the 15 month period from November 1997 to February
1999. The 59 Postinor-2 histories were collected over the 9 month period from June 1998 to February 1999.
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Given this “positive side” to the otherwise negative effects of emergency contraception,
concerns have occasionally been raised as to whether a “more tolerable” emergency
contraceptive method might not, in effect, remove any incentive for women to shift to routine
family planning methods. Though this argument fails to address the broader ethical issues
surrounding choice, putting such issues aside for the moment, the question remains “is there
any basis for such an argument?
Judging from the results of this study, the evidence for a relationship between side effects and
the adoption of routine family planning remains weak. But even the information that does
exist suggests that the relationship reflects far more than side effects alone. Just as important
is the client’s previous exposure to routine contraception and, related to that, whether or not
the client ever returned to the heath center for subsequent counseling.
At the outset, it is important to emphasize that whatever impact side effects may have had on
the continued use or subsequent adoption of routine family planning methods, the
overwhelming majority of emergency contraception users eventually adopted a routine family
planning method, regardless of whether they used PC-4 or Postinor-2. Among regular family
planning users, for example, over 71 percent either continued with their method or chose
another. Among non-users of a family planning method, the transition to routine
contraception averaged 65 percent.
The differences that do emerge from the present study, seem to vary with, on the one hand,
the type of emergency contraception method used and, on the other, whether the client was a
regular family planning user. Among those reporting no prior use of contraceptives, for
example, the differences between PC-4 and Postinor-2 users were practically non-existent.
Both were equally likely to return to the health facility for their recommended “follow-up
visit”; and both were equally likely to accept more effective (typically hormonal) family
planning methods. But among regular family planning users, the reactions to PC-4 and
Postinor-2 were somewhat different. The PC-4 users, for example, were less likely than
Postinor-2 users to skip their follow-up visit and less likely to leave without having accepted
a family planning method.
Why these divergences should exist is not entirely clear. One hypothesis may be that anyone
unaccustomed to a hormonal method (or even those accustomed to them, but with fewer side
effects than PC-4), is more likely to seek medical advice following emergency contraception
because they are more likely to experience side effects with which they are unfamiliar. Those
family planning users who received Postinor-2, by contrast, would not only have already been
familiar with hormonal methods but less likely to encounter anything unfamiliar, given the
fewer side effects of Postinor-2 in general.
The transition to more effective contraception: With respect to the transition from less to
more effective contraceptive methods, once again the similarities across groups far outweigh
any differences between them. Among all women who returned for their follow-up visit and
chose a family planning method, the adoption of highly effective, essentially hormonal
methods, reached levels of 90 percent and above. While this transition might be welcomed at
some levels, one major concern expressed by Ahmed et al (1998: 28-29) is that it is taking
place at the expense of barrier methods. Obviously, in areas of high STI prevalence, any
reduction in condom use must be examined carefully to ensure that the trend does not
continue. In the present case, the problem is a general one among emergency contraception
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users as a whole. Regardless of whether the product is PC-4 or Postinor-2, health care
providers must not allow the apparent dissatisfaction with less effective methods to
discourage condom use among former users of emergency contraception.
Preferences for emergency contraception products: The last issue to be addressed in the
study was the overall attitude of emergency contraception users towards the methods
themselves. Did fewer side effects correlate with a greater appreciation for the product; or
with an increased likelihood that it would be recommended to friends and relatives?

To begin with, it is important to acknowledge that responses to questions on client
satisfaction often serve as poor indicators of how clients truly feel about a product or service.
The same may very well be true with the present data, which consist of responses to queries
as to whether the client would ever recommend emergency contraception to a friend.
Nevertheless, client histories once again showed only minor differences in the relative appeal
of the two products. Of the 59 Postinor-2 users who returned to follow up, only one said she
would not recommend the method to a friend; the reason given being method failure. A
slightly higher percentage of former PC-4 users (7 out of 209) said they would not
recommend the method. In this case, the principal reason given was side effects and the
failure to prevent pregnancy. In both cases, however, method approval exceeded 95 percent.

Conclusions:

The results of this study clearly show that there is little relationship between the side effects
of an emergency contraception product, clients’ responses to that method, and the demands
on the service delivery system. Nor do the data support any of the theories associating the
severity of side effects with either aversion to the method or a reduction in its repeat use.
In retrospect, the findings of this study could have even been stronger had the research design
allowed for measuring repeat use directly, rather than relying on proxy variables such as
return to follow-up and adoption/continuation of family planning methods. Because no such
data was collected during the introduction of PC-4, however, there would have been no basis
for comparison, even if the present design had been modified. But by the same token, the
proxy variables used in this study are probably a more realistic indicators than repeat-use, of
the kinds of differences likely to result from the use of the two methods. Why? Because the
findings of a parallel study on prophylactic use of emergency contraception pills, suggest that
repeat use typically derives from multiple factors ranging from accessibility to the method to
an individual’s current contraceptive behavior or even reproductive health circumstances
(Skibiak et al 1999).
Another point worth noting, however, relates to the issue of repeat use and the rights of
individuals to address their own individual reproductive health needs. Much of the literature
on emergency contraception assumes that the most appropriate use of the method is in
accordance with what its name implies – emergencies. In fact, it is precisely this assumption
that underlies the fears and suspicions associated with a “more tolerable” or “side-effect free”
emergency contraception method. The fact of the matter, however, is that for some women,
repeat use of emergency contraception may very well be the most appropriate strategy to meet
their own reproductive health circumstances. These may include women whose sexual
activity is sporadic; women who prefer routine use of natural family planning methods; or
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even for women whose regularly use condoms, but occasionally experience breakage. For
these women, the choice is not between emergency contraception and a “more effective
method”, it is between emergency contraception and an unwanted pregnancy, or even unsafe
abortion. Providers must, therefore, be equipped to provide these with women with the
information, services, and methods they request.
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6. FROM RESEARCH TO ACTION: THE NEXT
STEPS
What, then, do the results of this study suggest about service delivery and behavioral
implications of PC-4 and Postinor-2? Are they truly comparable? Are the lessons learned
from having introduced one really comparable to the results of having introduced the other?
From a user-perspective, there is little doubt that despite the very distinctive nature of the two
products, their effect on user attitudes and behavior has been virtually indistinguishable. At
present, family planning users in Zambia display few preferences or aversions towards either
product. They adopt both at comparable rates and, after having used them, manifest few if
any differences in their appreciation of either product; in their decision to adopt a family
planning method, or even in their choice of method itself.
From a provider-perspective, similarities also overshadow differences. Provider training was
virtually identical for both methods, and indeed most of those trained to provide Postinor-2
had already been trained in emergency contraception either under Phase One of this project,
or by CARE/Zambia as part of their program of technical support to the Zambia Central
Board of Health. Even more important, however, the absence of differences in client attitudes
and behavior would obviate any need for providers to vary their support to users of either
method. Indeed, the only alarming trend to emerge from the use of emergency contraception –
that of eschewing barrier methods for more “effective” hormonal methods – was common to
both methods.
And finally, from a service delivery perspective, recent policy decisions by Schering even call
into question earlier assumptions that de-medicalizing emergency contraception would hinge
on the selection of one product over the other. In June 1998, two months after the launching
of this study, Schering bowed to pressure from the British Parliament by expanding the range
of providers authorized to prescribe PC-4 to include nurses and pharmacists. Though this
move does not go so far as to permit over the counter sales of the product, it still represents a
major step forward in enhancing women’s access to the product. And if indeed this policy
should eventually be extended to Schering’s operations worldwide, then the question of
access may represent less of a rationale for exploring alternative emergency contraception
products.
What then, should one conclude from these findings? Should one conclude that the
programmatic differences associated with introducing progestin or Yuzpe regimens of
emergency contraception are insignificant – perhaps even nonexistent? Throughout the study,
the argument has consistently been made that the similarities between PC-4 and Postinor-2,
at the service delivery level, greatly overshadow their differences. And, for all of the reasons
cited above, this contention certainly holds true. But there are differences between the two
products; some of which could very well have implications that go far beyond the service
delivery aspects discussed here.
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One such difference relates to the issue of supply and logistics. Under this study, the
procurement of PC-4 and Postinor-2 stocks was made possible through the financial support
of Britain’s Overseas Development Administration (now DfID) and WHO/HRP. From a
service delivery perspective, therefore, product costs and the logistics of supplying
commodities remained outside the present focus of inquiry. In the real world, however, and
certainly from a programmatic perspective, costs and logistics are very much an issue. What
is more, they are issues that affect progestin-only and combined oral contraceptives quite
differently.
Technically speaking, PC-4 consists of nothing more than four of Schering’s high-dose oral
contraceptives, Neogynon, repackaged and marketed under a different brand name (Camp
1998: 225). Because the price of each tablet sold under the name PC-4 is many times more
than that of a tablet contained in a full cycle of Neogynon, the fact remains that in the case of
combined emergency contraception regimens, substitution is always an option – either by the
same number of high dose contraceptives, or by doubling the number of low-dose pills. In
the event of product stockouts or in an environment of cost cutting, PC-4 can always be
replaced – and done so more cheaply – by existing supplies.
Postinor-2, by contrast, has no true equivalent within the range of methods typically available
at health care facilities. One could, it is true, administer the same level of hormones by
substituting 20-25 low-dose progestin-only oral contraceptive pills for each Postinor-2 tablet,
but it has not been established whether the progestins contained in the brands currently
available in Zambia (Microlut and Microval) would be metabolized in the same way
(Ellertson 1998) or even whether women would be willing to ingest that many pills at one
time.9 Furthermore, in contrast to PC-4, substitution would not provide any cost savings for
the simple reason that the unit price (to donors) of one packet of Postinor-2 and that of a
cycle of minipills is essentially the same.

There is, however, one final distinction to be made between PC-4 and Postinor-2 – a
distinction that could not be addressed within this study, but one that would nevertheless
merit attention in any comparison of the two products. It is the fairly solid body of evidence
suggesting that in addition to reducing certain side effects, a levonorgestrel-only regimen of
emergency contraception may actually be more effective than the Yuzpe method at averting
pregnancies (Von Hertzen 1998: 222-232; Von Hertzen et al 1998: 1939). The decision not
to compare the efficacy of the two regimens in this study was taken for two reasons. In the
first place, a detailed comparison of the methods’ technical attributes would clearly have
fallen outside the present scope of inquiry, which was to gauge the service delivery
implications of method introduction. Secondly, the need for such a study was mooted by the
fact that WHO (Task Force 1998: 428-433) had already concluded a randomized, doubleblind study on this issue among 2,000 women in 14 countries. The results of this study,
which were published three months after the start-up of the present study, confirmed the
findings of previous research. They showed that the efficacy of levonorgestrel was greater
than that of the Yuzpe regimen in terms of both crude and adjusted pregnancy rates and
pregnancies prevented10.
9

It is worth noting, however, that in focus group discussions carried out among clients at the PC-4 clinics,
women showed little aversion to the notion of ingesting 20-25 minipills, if doing so was to prove more effective
at preventing pregnancy and less prone to side-effects than taking PC-4.
10
Crude pregnancy rates were 3.2 percent among those assigned to the Yuzpe regimen, compared to 1.1
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In 1998, von Hertzen concluded her review of alternative emergency contraception regimens
by arguing that research had little value “if its results are not put into practice for the benefit
of people”. In looking beyond the purely technical attributes of the two emergency
contraception products discussed here, this study has shown that the opportunities are wide
open for making emergency contraception a reality for women. There are, it is true,
substantive differences between the two products. The side effects are different; the efficacy
may be different, and the implications for supply and logistics may be different. But perhaps
most important of all is the fact that at the service delivery level, these differences do not call
for new training programs, different client support mechanisms, or even distinctive strategies
for the dissemination of information. Women display few preferences towards either product,
they adopt both at comparable rates and, after having used them, manifest few if any
differences in their decision to adopt a family planning method, or even in their choice of
method itself. From the provider and service delivery perspective, similarities also
overshadow differences.
What the findings of this study show therefore, is that the body of evidence collected to date
on the service delivery implications of PC-4 is comparable and relevant to that associated
with the delivery of Postinor-2. The challenge now, rests with Zambia’s regulatory authorities
to apply these lessons so that emergency contraception finally becomes a reproductive health
option open to all women.

percent among those assigned levonorgestrel; while the proportion of pregnancies prevented (compared with the
expected number without treatment) declined from 85 percent among women with the levonorgestrel regimen to
57 percent among those with the Yuzpe regimen (Task Force: 1998: 428). Comparing the WHO results with this
study is complicated by the fact that the present study did not control for when during the participants’ menstrual
cycle unprotected sex occurred; nor did it exclude emergency contraception users who might have had
unprotected sex more than once during the same cycle. Nevertheless, for informational purposes, only one
Postinor-2 user (2 percent) became pregnant despite having taken the method within the first 72 hours of
unprotected sex. This figure contrasts with 9 pregnancies among users of PC-4 (4.5 percent) – though all but
one later admitted to having taken the method after 72 hours. In short, the study provided no basis for
concluding that one regimen was any more effective than the other at preventing pregnancy.
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